In the last trading session, 77507.0 shares of the Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) were traded, and its beta was 0.27. Most recently the company’s share price was $1.89, and it changed around -$0.1 or -5.03% from the last close, which brings the market valuation of the company to $10.78M. BCLI currently trades at a discount to its 52-week high of $11.89, offering almost -529.1% off that amount. The share price’s 52-week low was $1.05, which indicates that the current value has risen by an impressive 44.44% since then. We note from Brainstorm Cell Therapeutics, Inc’s average daily trading volume that its 10-day average is 58480.0 shares, with the 3-month average coming to 110.73K.
Brainstorm Cell Therapeutics, Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended BCLI as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Brainstorm Cell Therapeutics, Inc is expected to report earnings per share of -0.27 for the current quarter.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) trade information
Instantly BCLI has showed a red trend with a performance of -5.03% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.2400 on recent trading dayincreased the stock’s daily price by 15.63%. The company’s shares are currently down -16.74% year-to-date, but still down -6.44% over the last five days. On the other hand, Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) is 21.94% up in the 30-day period. We can see from the shorts that 0.11 million shares have been sold at a short interest cover period of 1.25 day(s).
Brainstorm Cell Therapeutics, Inc (BCLI) estimates and forecasts
Brainstorm Cell Therapeutics, Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -66.57 percent over the past six months and at a 60.65% annual growth rate that is well above the industry average of 16.50%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 10.56%.
BCLI Dividends
Brainstorm Cell Therapeutics, Inc’s next quarterly earnings report is expected to be released in February.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 9.04% of Brainstorm Cell Therapeutics, Inc shares, and 13.90% of them are in the hands of institutional investors. The stock currently has a share float of 15.28%. Brainstorm Cell Therapeutics, Inc stock is held by 44.0 institutions, with ARMISTICE CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 12.2302% of the shares, which is about 7.92 million shares worth $2.68 million.
VANGUARD GROUP INC, with 2.3334% or 1.51 million shares worth $0.51 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Fidelity Extended Market Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 70.73 shares worth $0.13 million, making up 1.24% of all outstanding shares. On the other hand, Fidelity Extended Market Index Fund held roughly 28.25 shares worth around $53383.0, which represents about 0.50% of the total shares outstanding.
